The Europe Biosimilars Market would witness market growth of 23.6% CAGR during the forecast period (2022-2028).
The prevalence of autoimmune conditions like rheumatoid arthritis & ankylosing spondylitis is rising, fueling the growth of the biosimilars market. For the treatment of chronic pain in arthritis, biosimilars like infliximab-dyyb (Inflectra), infliximab-axxq (Avsola), infliximab-qbtx (Ixifi), and infliximab-abda (Renflexis) are used. Moreover, the number of orthopedic hospitals and diagnostic facilities is growing, which helps with disease diagnosis and treatment rates. As a result, the prevalence of debilitating autoimmune diseases is rising, and hospitals are becoming more numerous.
Diabetes incidence is steadily increasing, which is boosting the demand for insulin biosimilars. In addition, diabetes patients have a cost-effective option in the form of biosimilar insulin analogs. Because of the rising prevalence of diabetes as well as recent product approvals, the market for biosimilars is expanding.
Europe's diverse healthcare systems & sizable biosimilars markets serve as valuable case studies for various approaches to biosimilars policy. Sales of biosimilars reflect Europe's market leadership in terms of legislation and regulations. The biosimilars market in the region is more developed due to the high focus on healthcare. With more approved treatments than any other continent, Europe has established the benchmark. A large quantity of 10% of the region's total biologics market is currently made up of biosimilars, the majority of which have appeared in the last five years.
The Germany market dominated the Europe Biosimilars Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3,862.8 million by 2028. The UK market is estimated to witness a CAGR of 22.6% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 24.6% during (2022 - 2028).
Based on Application, the market is segmented into Oncology Diseases, Blood Disorders, Chronic & Autoimmune Diseases and Others. Based on Type, the market is segmented into Monoclonal Antibodies, Granulocyte-Colony Stimulating Factor, Erythropoietin, Human Growth Hormone, Insulin and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Biosimilars Market will Hit $59 Billion by 2028, at a CAGR of 24.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Biocon Limited, Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, Intas Pharmaceutical Ltd, Novartis AG (Sandoz), Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd. and Fresenius SE & Co. KGaA
Scope of the Study
Market Segments Covered in the Report:
By Application
- Oncology Diseases
- Blood Disorders
- Chronic & Autoimmune Diseases
- Others
By Type
- Monoclonal Antibodies
- Granulocyte-Colony Stimulating Factor
- Erythropoietin
- Human Growth Hormone
- Insulin
- Others
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Amgen, Inc.
- Biocon Limited
- Dr. Reddy’s Laboratories Ltd.
- Eli Lilly and Company
- Intas Pharmaceutical Ltd
- Novartis AG (Sandoz)
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Fresenius SE & Co. KGaA
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Biosimilars Market, by Application
1.4.2 Europe Biosimilars Market, by Type
1.4.3 Europe Biosimilars Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Acquisition and Mergers
3.2.4 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, Jun – 2022, Aug) Leading Players
Chapter 4. Europe Biosimilars Market by Application
4.1 Europe Oncology Diseases Market by Country
4.2 Europe Blood Disorders Market by Country
4.3 Europe Chronic & Autoimmune Diseases Market by Country
4.4 Europe Others Market by Country
Chapter 5. Europe Biosimilars Market by Type
5.1 Europe Monoclonal Antibodies Market by Country
5.2 Europe Granulocyte-Colony Stimulating Factor Market by Country
5.3 Europe Erythropoietin Market by Country
5.4 Europe Human Growth Hormone Market by Country
5.5 Europe Insulin Market by Country
5.6 Europe Others Market by Country
Chapter 6. Europe Biosimilars Market by Country
6.1 Germany Biosimilars Market
6.1.1 Germany Biosimilars Market by Application
6.1.2 Germany Biosimilars Market by Type
6.2 UK Biosimilars Market
6.2.1 UK Biosimilars Market by Application
6.2.2 UK Biosimilars Market by Type
6.3 France Biosimilars Market
6.3.1 France Biosimilars Market by Application
6.3.2 France Biosimilars Market by Type
6.4 Russia Biosimilars Market
6.4.1 Russia Biosimilars Market by Application
6.4.2 Russia Biosimilars Market by Type
6.5 Spain Biosimilars Market
6.5.1 Spain Biosimilars Market by Application
6.5.2 Spain Biosimilars Market by Type
6.6 Italy Biosimilars Market
6.6.1 Italy Biosimilars Market by Application
6.6.2 Italy Biosimilars Market by Type
6.7 Rest of Europe Biosimilars Market
6.7.1 Rest of Europe Biosimilars Market by Application
6.7.2 Rest of Europe Biosimilars Market by Type
Chapter 7. Company Profiles
7.1 Fresenius SE & Co. KGaA
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.1.5 Recent strategies and developments:
7.1.5.1 Approvals and Trials:
7.1.5.2 Product Launches and Product Expansions:
7.1.5.3 Acquisition and Mergers:
7.2 Dr. Reddy’s Laboratories Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Product Launches and Product Expansions:
7.3 Pfizer, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional & Segmental Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.3.5.2 Product Launches and Product Expansions:
7.3.5.3 Acquisition and Mergers:
7.4 Amgen, Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Approvals and Trials:
7.4.5.2 Product Launches and Product Expansions:
7.4.5.3 Acquisition and Mergers:
7.5 Teva Pharmaceutical Industries Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.5.5.2 Approvals and Trials:
7.5.5.3 Product Launches and Product Expansions:
7.6 Eli Lilly And Company
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.7 Merck & Co., Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expenses
7.7.5 Recent strategies and developments:
7.7.5.1 Product Launches and Product Expansions:
7.8 Novartis AG (Sandoz)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.8.5.2 Approvals and Trials:
7.9 Biocon Limited
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Partnerships, Collaborations, and Agreements:
7.9.2.2 Product Launches and Product Expansions:
7.9.2.3 Acquisition and Mergers:
7.10. Intas Pharmaceutical Ltd.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Partnerships, Collaborations, and Agreements:
7.10.2.2 Product Launches and Product Expansions:
TABLE 1 Europe Biosimilars Market, 2018 - 2021, USD Million
TABLE 2 Europe Biosimilars Market, 2022 - 2028, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Biosimilars Market
TABLE 4 Product Launches And Product Expansions– Biosimilars Market
TABLE 5 Acquisition and Mergers– Biosimilars Market
TABLE 6 Approvals and Trials – Biosimilars Market
TABLE 7 Europe Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 8 Europe Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 9 Europe Oncology Diseases Market by Country, 2018 - 2021, USD Million
TABLE 10 Europe Oncology Diseases Market by Country, 2022 - 2028, USD Million
TABLE 11 Europe Blood Disorders Market by Country, 2018 - 2021, USD Million
TABLE 12 Europe Blood Disorders Market by Country, 2022 - 2028, USD Million
TABLE 13 Europe Chronic & Autoimmune Diseases Market by Country, 2018 - 2021, USD Million
TABLE 14 Europe Chronic & Autoimmune Diseases Market by Country, 2022 - 2028, USD Million
TABLE 15 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 16 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 17 Europe Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 18 Europe Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 19 Europe Monoclonal Antibodies Market by Country, 2018 - 2021, USD Million
TABLE 20 Europe Monoclonal Antibodies Market by Country, 2022 - 2028, USD Million
TABLE 21 Europe Granulocyte-Colony Stimulating Factor Market by Country, 2018 - 2021, USD Million
TABLE 22 Europe Granulocyte-Colony Stimulating Factor Market by Country, 2022 - 2028, USD Million
TABLE 23 Europe Erythropoietin Market by Country, 2018 - 2021, USD Million
TABLE 24 Europe Erythropoietin Market by Country, 2022 - 2028, USD Million
TABLE 25 Europe Human Growth Hormone Market by Country, 2018 - 2021, USD Million
TABLE 26 Europe Human Growth Hormone Market by Country, 2022 - 2028, USD Million
TABLE 27 Europe Insulin Market by Country, 2018 - 2021, USD Million
TABLE 28 Europe Insulin Market by Country, 2022 - 2028, USD Million
TABLE 29 Europe Others Market by Country, 2018 - 2021, USD Million
TABLE 30 Europe Others Market by Country, 2022 - 2028, USD Million
TABLE 31 Europe Biosimilars Market by Country, 2018 - 2021, USD Million
TABLE 32 Europe Biosimilars Market by Country, 2022 - 2028, USD Million
TABLE 33 Germany Biosimilars Market, 2018 - 2021, USD Million
TABLE 34 Germany Biosimilars Market, 2022 - 2028, USD Million
TABLE 35 Germany Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 36 Germany Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 37 Germany Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 38 Germany Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 39 UK Biosimilars Market, 2018 - 2021, USD Million
TABLE 40 UK Biosimilars Market, 2022 - 2028, USD Million
TABLE 41 UK Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 42 UK Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 43 UK Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 44 UK Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 45 France Biosimilars Market, 2018 - 2021, USD Million
TABLE 46 France Biosimilars Market, 2022 - 2028, USD Million
TABLE 47 France Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 48 France Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 49 France Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 50 France Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 51 Russia Biosimilars Market, 2018 - 2021, USD Million
TABLE 52 Russia Biosimilars Market, 2022 - 2028, USD Million
TABLE 53 Russia Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 54 Russia Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 55 Russia Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 56 Russia Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 57 Spain Biosimilars Market, 2018 - 2021, USD Million
TABLE 58 Spain Biosimilars Market, 2022 - 2028, USD Million
TABLE 59 Spain Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 60 Spain Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 61 Spain Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 62 Spain Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 63 Italy Biosimilars Market, 2018 - 2021, USD Million
TABLE 64 Italy Biosimilars Market, 2022 - 2028, USD Million
TABLE 65 Italy Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 66 Italy Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 67 Italy Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 68 Italy Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 69 Rest of Europe Biosimilars Market, 2018 - 2021, USD Million
TABLE 70 Rest of Europe Biosimilars Market, 2022 - 2028, USD Million
TABLE 71 Rest of Europe Biosimilars Market by Application, 2018 - 2021, USD Million
TABLE 72 Rest of Europe Biosimilars Market by Application, 2022 - 2028, USD Million
TABLE 73 Rest of Europe Biosimilars Market by Type, 2018 - 2021, USD Million
TABLE 74 Rest of Europe Biosimilars Market by Type, 2022 - 2028, USD Million
TABLE 75 key information – Fresenius SE & Co. KGaA
TABLE 76 key information – Dr. Reddy’s Laboratories Ltd.
TABLE 77 Key Information – Pfizer, Inc.
TABLE 78 Key Information – Amgen, Inc.
TABLE 79 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 80 Key Information – Eli Lilly And Company
TABLE 81 KEY INFORMATION - MERCK & CO., INC.
TABLE 82 Key Information – Novartis AG
TABLE 83 Key Information – Biocon Limited
TABLE 84 Key Information – Intas Pharmaceutical Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2018-2022)
FIG 4 Key Strategic Move: (Partnerships, Collaborations & Agreements : 2018, Jan – 2022, Aug) Leading Players
FIG 5 Recent strategies and developments: Fresenius SE & Co. KGaA
FIG 6 Recent strategies and developments: Dr. Reddy’s Laboratories Ltd.
FIG 7 Recent strategies and developments: Pfizer, Inc.
FIG 8 Recent strategies and developments: Amgen, Inc.
FIG 9 Recent strategies and developments: Teva Pharmaceuticals Industries Ltd.
FIG 10 Recent strategies and developments: Novartis AG
FIG 11 Recent strategies and developments: Biocon Limited
FIG 12 Recent strategies and developments: Intas Pharmaceutical Ltd.